Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands			1 Months Ended	6 Months Ended
	May 02, 2020	Sep. 11, 2019	Jul. 31, 2019	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 10, 2019	Jun. 30, 2019	Mar. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Entity Listings [Line Items]
Retained Earnings (Accumulated Deficit)				$ 288,343		$ 273,422
Working capital				38,700
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest				97,693	$ 104,758	$ 111,247		$ 131,759	$ 161,236		$ 92,246
Cash, Cash Equivalents, and Short-term Investments				20,300
Promissory note amount				24,400
Ownership percentage, description		On September 11, 2019, Lineage’s ownership percentage decreased from 24% to 16% when it sold 4.0 million shares of OncoCyte common stock. Accordingly, as the ownership percentage was reduced to less than 20%, Lineage is no longer considered to exercise significant influence over OncoCyte and is now accounting for its OncoCyte holdings as marketable equity securities.
Deferred Revenue				$ 97
Lease payment rate, description				For lease classification determination, Lineage continues to use (i) greater to or equal to 75% to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) greater to or equal to 90% to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset
Accounting Standards Update 2016-02 [Member]
Entity Listings [Line Items]
Leasehold improvements, book value										$ 1,900
Corresponding lease liabilities										2,000
ASC 840 [Member]
Entity Listings [Line Items]
Lease cumulative effect adjustment										$ 100
OncoCyte Corporation [Member]
Entity Listings [Line Items]
Ownership percentage		16.00%		5.40%			24.00%
Number of stock sold		4,000,000.0	2,250,000	4,800,000
Controlled Equity Offering [Member] | Sales Agreement [Member] | Cantor Fitzgerald And Co Member [Member]
Entity Listings [Line Items]
Obligated common shares	$ 25,000